<DOC>
	<DOCNO>NCT02071173</DOCNO>
	<brief_summary>The objective NAVIGATE X4 Clinical Study gather data establish safety , performance effectiveness ACUITY™ X4 quadripolar coronary venous lead RELIANCE 4-FRONT™ ventricular defibrillation lead satisfy FDA requirement pre-market submission . Additionally , data study use support post-market approval requirement ACUITY X4 RELIANCE 4-FRONT lead .</brief_summary>
	<brief_title>Evaluation ACUITY™ X4 Quadripolar Coronary Venous Leads RELIANCE™ 4-FRONT Defibrillation Leads</brief_title>
	<detailed_description />
	<criteria>Subjects indicate CRTD fulfill one follow 5 criterion [ 1 ] : 1 . Subject LVEF le equal 35 % , sinus rhythm , LBBB QRS duration great equal 150 m , NYHA class II , III ambulatory IV symptom GDMT* 2 . Subject LVEF le equal 35 % , sinus rhythm , LBBB QRS duration 120 149 m , NYHA class II , III , ambulatory IV symptom GDMT* 3 . Subject LVEF le equal 35 % , sinus rhythm , nonLBBB pattern QRS duration great equal 150 m , NYHA class III/ ambulatory class IV symptom GDMT* 4 . Subject atrial fibrillation LVEF le equal 35 % GDMT* ) subject require ventricular pace otherwise meet CRT criterion [ list ] b ) AV nodal ablation pharmacologic rate control allow near 100 % ventricular pacing CRT 5 . Subject GDMT* LVEF less equal 35 % undergoing new device placement anticipate requirement significant ( &gt; 40 % ) ventricular pace *GDMT = Guidelinedirected medical therapy ( formerly know optimal pharmaceutical therapy ( OPT ) ) , represent optimal medical therapy define ACCF/ AHA guidelinerecommended therapy ( primarily Class I ) Subject intend receive ACUITY X4 LV lead RELIANCE 4FRONT RV lead ( optional Study Phase 1 ) BSC CRTD quad header initial ( de novo ) cardiac implant Subject willing capable providing inform consent ( include use legally authorize representative ( LAR ) documentation inform consent ) participate test associated investigation approve center interval define protocol Subject age 18 , legal age give inform consent specific state national law Subjects meet one follow criterion exclude clinical study . Subject know suspected sensitivity dexamethasone acetate ( DXA ) Subject mechanical tricuspid heart valve Subject enrol concurrent study , exception local mandatory governmental registry observational studies/registries* conflict affect follow : Schedule procedure Study ( i.e . cause additional miss visit ) ; Study outcome ( i.e . involve medication could affect heart rate subject ) ; Conduct Study per GCP/ ISO 14155:2011/ 21 CFR 812 , local regulation Subject currently active heart transplant list Subject document life expectancy less twelve month Women childbearing potential might pregnant time study enrollment CRTD System implant ( method assessment upon physician 's discretion ) Subjects currently require chronic dialysis *Sponsors studies/registries inform Boston Scientific must inform investigator parallel conduct project subject project 's basic nature . The decision desire mandatory governmental registry observational study/ registry conflict exclusion criterion enrol investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>